3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Polycythemia Vera
2
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Interventions
ruxolitinib
6
fludarabine phosphate
2
Whole-Body Irradiation
2
Tacrolimus
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Injections
2
Cyclophosphamide
2
Busulfan
2
Biopsy
2
veliparib
1
piperine
1
iadademstat
1
fludarabine
1
fedratinib
1
demethoxycurcumin
1
decitabine and cedazuridine drug combination
1
bomedemstat
1
Transplantation
1
Topotecan
1
Stem Cell Transplantation
1
Sirolimus
1
Resistance Training
1
Radiotherapy
1
N(4)-oleylcytosine arabinoside
1
Methotrexate
1
Melphalan
1
Liposomes
1
INCB057643
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocythemia, Essential
×
bomedemstat
×
90 days
×
Clear all
NCT06351631
2026-04-02
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3
Recruiting
400 enrolled